Mario Mercuri focuses on Surgery, Chemotherapy, Osteosarcoma, Sarcoma and Internal medicine. His is involved in several facets of Surgery study, as is seen by his studies on Ifosfamide, Survival rate, Amputation, Retrospective cohort study and Survival analysis. The Chemotherapy study combines topics in areas such as Neoadjuvant therapy, Multivariate analysis, Primary tumor and Single institution.
His Osteosarcoma research incorporates themes from Methotrexate, Cisplatin, Regimen, Disease and Pathologic fracture. His Sarcoma research is multidisciplinary, relying on both Cancer, Metastasis and Radiation therapy. Mario Mercuri combines subjects such as Gastroenterology and Oncology with his study of Internal medicine.
His primary areas of study are Surgery, Chemotherapy, Osteosarcoma, Sarcoma and Internal medicine. Amputation, Radiation therapy, Survival rate, Implant and Retrospective cohort study are subfields of Surgery in which his conducts study. His Chemotherapy research incorporates elements of Regimen and Adjuvant.
His Osteosarcoma research includes themes of Methotrexate, Cisplatin and Primary tumor. His study in Sarcoma is interdisciplinary in nature, drawing from both Cancer, Vincristine and Induction chemotherapy. The various areas that he examines in his Internal medicine study include Gastroenterology and Oncology.
His scientific interests lie mostly in Surgery, Sarcoma, Osteosarcoma, Chemotherapy and Orthopedic surgery. As part of one scientific family, Mario Mercuri deals mainly with the area of Sarcoma, narrowing it down to issues related to the Doxorubicin, and often Vincristine. His biological study spans a wide range of topics, including Spindle cell sarcoma, Fibrous dysplasia and Chondrosarcoma.
His Chemotherapy study is associated with Internal medicine. Mario Mercuri has researched Internal medicine in several fields, including Gastroenterology and Standard treatment. His work deals with themes such as Randomized controlled trial and Methotrexate, which intersect with Ifosfamide.
Surgery, Sarcoma, Retrospective cohort study, Orthopedic surgery and Osteosarcoma are his primary areas of study. Surgery is closely attributed to Radiology in his study. His Sarcoma research integrates issues from Ifosfamide, Internal medicine, Chemotherapy and Clinical endpoint.
His work carried out in the field of Chemotherapy brings together such families of science as Immunology and Oncology. Mario Mercuri has included themes like Adjuvant, Giant cell, Radiography and Lesion in his Retrospective cohort study study. His research integrates issues of Cancer, Disease, Rare disease, Bone marrow and Resorption in his study of Orthopedic surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Primary bone osteosarcoma in the pediatric age: State of the art
Alessandra Longhi;Costantino Errani;Massimiliano De Paolis;Mario Mercuri.
Cancer Treatment Reviews (2006)
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Gaetano Bacci;Alessandra Longhi;Michela Versari;Mario Mercuri.
Platelet-derived growth factors enhance proliferation of human stromal stem cells.
Enrico Lucarelli;Amira Beccheroni;Davide Donati;Luca Sangiorgi.
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Stefano Ferrari;Sigbjorn Smeland;Mario Mercuri;Franco Bertoni.
Journal of Clinical Oncology (2005)
Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review
Eric R. Henderson;John S. Groundland;Elisa Pala;Jeremy A. Dennis.
Journal of Bone and Joint Surgery, American Volume (2011)
Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin
Gaetano Bacci;Piero Picci;Stefano Ferrari;Pietro Ruggieri M.D..
Giant cell tumor of the extremity: A review of 349 cases from a single institution.
Costantino Errani;Pietro Ruggieri;Marco Antonio Nogales Asenzio;Angelo Toscano.
Cancer Treatment Reviews (2010)
Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival
Stefano Ferrari;Antonio Briccoli;Mario Mercuri;Franco Bertoni.
Journal of Clinical Oncology (2003)
Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities the istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin
G. Bacci;P. Picci;P. Ruggieri;M. Mercuri.
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities.
P Picci;T Böhling;G Bacci;S Ferrari.
Journal of Clinical Oncology (1997)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: